Potential Therapeutic Targets in Uterine Sarcomas.

about

Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.Next generation of network medicine: interdisciplinary signaling approaches.Non-canonical WNT6/WNT10A signal factor expression in EBV+ post-transplant smooth muscle tumors.

P2860

Q38765107-60BDFD55-8907-486E-940D-799ED3746509 Q39010533-4506993D-EFD2-4447-AB88-BAF04DDB9AA0 Q55286123-4EF9A7B8-A202-4A9D-AFF9-62403E5B32CD

P2860

Potential Therapeutic Targets in Uterine Sarcomas.

Item

http://www.wikidata.org/entity/Q36245677

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Potential Therapeutic Targets in Uterine Sarcomas.

@ast

Potential Therapeutic Targets in Uterine Sarcomas.

@en

type

Item

label

Potential Therapeutic Targets in Uterine Sarcomas.

@ast

Potential Therapeutic Targets in Uterine Sarcomas.

@en

prefLabel

Potential Therapeutic Targets in Uterine Sarcomas.

@ast

Potential Therapeutic Targets in Uterine Sarcomas.

@en

P1476

Potential Therapeutic Targets in Uterine Sarcomas

@en

P2093

Frédéric Amant

http://www.w3.org/2001/XMLSchema#string

Tine Cuppens

http://www.w3.org/2001/XMLSchema#string

P2860

Wnt/beta-catenin signaling and small molecule inhibitors

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

The first 30 years of p53: growing ever more complex

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.

Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

P304

243298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2015/243298

http://www.w3.org/2001/XMLSchema#string

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

Sandra Tuyaerts

P577

2015-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283958844

http://www.w3.org/2001/XMLSchema#string

P698

26576131

http://www.w3.org/2001/XMLSchema#string

P932

4632006

http://www.w3.org/2001/XMLSchema#string

Potential Therapeutic Targets in Uterine Sarcomas.

about

P2860

P2860

Potential Therapeutic Targets in Uterine Sarcomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932